H3K9 Lactylation: Microglial Metabolic‑Epigenetic Positive‑Feedback Loops That Aggravate Ischemic Brain Injury

Metabolic Reprogramming and Epigenetic Alterations in Ischemic‑Stroke Model Systems

Acute ischaemic stroke accounts for approximately 80 % of stroke‑related mortality within pre‑clinical population‑model analyses. Its pathological progression involves ischaemia‑reperfusion insults alongside robust neuroinflammatory responses inside central‑nervous‑system tissue environments.

Microglia represent resident innate‑immune cell populations inside the brain, and imbalanced M1‑ versus M2‑polarization status acts as a central driver for propagating neuroinflammatory phenotypes. Activated microglia undergo profound intracellular metabolic reprogramming following ischaemic insult in experimental animal‑model systems.

Histone lactylation constitutes lactate‑driven post‑translational epigenetic modification that connects cellular metabolic states with downstream gene‑transcription programmes. Early mechanistic questions remained open regarding its concrete molecular roles within ischaemic‑stroke‑related microglial‑activation processes.

Researchers deployed mouse middle‑cerebral‑artery‑occlusion‑reperfusion models and in‑vitro oxygen‑glucose‑deprivation‑re‑oxygenation cell‑culture assays for investigative work. SMEK1 protein abundance inside microglia displayed an initial increase followed by a gradual reduction after reperfusion‑challenge exposure.

SMEK1 concentrations reached minimal levels on the third post‑reperfusion experimental day, accompanied by elevated intracellular lactate pools and globally enhanced histone‑lactylation signals. Among these modified histone marks, H3K9 lactylation exhibited the most prominent signal elevation in tested microglial cell populations.

The miR‑125a‑5p/SMEK1 Axis Drives Lactate Accumulation and H3K9 Lactylation

Following ischaemic‑reperfusion experimental stimulation, microglial miR‑125a‑5p transcript abundance undergoes measurable up‑regulation within sample cohorts. This microRNA directly targets 3'‑UTR sequences belonging to SMEK1 messenger RNA to suppress SMEK1 protein translation efficiency.

Loss‑of‑function SMEK1 status triggers significant PDK3 transcriptional up‑regulation inside affected microglia. Elevated PDK3 protein inhibits pyruvate‑dehydrogenase enzymatic activity and restrains mitochondrial oxidative‑phosphorylation flux, while glycolytic metabolic rates become distinctly amplified.

Enhanced glycolytic turnover generates large‑volume intracellular lactate accumulation, which in turn promotes bulk histone‑lactylation events, with pronounced enrichment observed for H3K9la marks. ChIP‑qPCR experimental datasets demonstrate H3K9la physically occupies promoter regions of Ldha and Hif‑1α gene loci.

H3K9‑lactylation‑associated chromatin remodelling facilitates transcriptional activation for both target genes. LDHA catalyses pyruvate‑to‑lactate conversion, whereas HIF‑1α serves as a master transcriptional regulator for broad glycolytic‑gene sets. These molecular events establish a self‑reinforcing positive‑feedback cascade: lactate → H3K9la → glycolytic‑gene expression → additional lactate production.

Functional Consequences of H3K9 Lactylation for Microglial Polarization and Neuroinflammation

Experimental functional assays indicate SMEK1‑deficient conditions trigger microglial phenotypic shift toward pro‑inflammatory M1‑polarized cellular states. Such cellular transformation brings elevated secretion of pro‑inflammatory mediators TNF‑α and IL‑6 alongside diminished anti‑inflammatory IL‑10 cytokine output.

Transgenic mice with microglia‑restricted SMEK1 over‑expression exhibit improved cerebral‑blood‑flow restoration, superior neurobehavioural scoring metrics and reduced infarct‑volume readouts after ischaemic‑reperfusion surgical challenge. Conversely, exogenous miR‑125a‑5p mimic administration exacerbates measurable brain‑tissue injury phenotypes in‑vivo.

Notably, H3K9la represents a microglia‑preferred lactylation mark under ischaemic‑stroke experimental conditions. This molecular signature differs from H4K12la marks documented within Alzheimer‑disease‑oriented model research, revealing cell‑type‑ and disease‑specific histone‑lactylation‑profile characteristics.

Research‑Oriented Intervention Strategies Targeting the miR‑125a‑5p/SMEK1/H3K9la Axis

Pre‑clinical laboratory investigations tested intranasal delivery routes for miR‑125a‑5p inhibitor compounds. This intervention strategy restored SMEK1 protein abundance, dampened neuroinflammatory signalling and improved neuro‑functional behavioural parameters in ischaemic‑stroke mouse‑model cohorts.

Nevertheless, intranasal compound administration lacks intrinsic microglia‑cell‑selective delivery properties and can exert molecular influences upon additional central‑nervous‑system cell populations. Further technical development is required for cell‑type‑specific delivery platforms such as DNA‑origami‑based molecular carriers.

H3K9la also presents investigative value as a potential epigenetic biomarker for evaluating neuroinflammatory severity under ischaemic‑brain‑injury‑model experimental settings. Further mechanistic work remains needed to clarify dynamic temporal profiles and downstream gene‑regulatory networks governed by H3K9‑lactylation marks.

Experimental‑Reagent Requirements for Site‑Specific Histone‑Lactylation Epigenetic Studies

Site‑specific anti‑histone‑lactylation antibodies represent essential experimental reagents for molecular‑epigenetics investigative workflows. These validated immunological tools support multiple common laboratory‑assay formats including Western blot, immunohistochemistry, ChIP‑qPCR and CUT&Tag sequencing‑related sample processing.

Appropriate peptide‑competition or gene‑knockout negative‑control sample groups should be incorporated during experimental validation phases to confirm antibody epitope‑recognition specificity. Reliable batch‑to‑batch reagent consistency guarantees reproducible comparative analysis between control and ischaemia‑challenged biological‑sample cohorts.

Research‑Grade Reagent Portfolio for Histone‑Lactylation‑Focused Neuro‑Epigenetics Research

ANT BIO PTE. LTD. provides validated histone‑lactylation‑targeted recombinant‑antibody reagent sets dedicated exclusively to non‑clinical neuro‑epigenetics laboratory‑research projects. These reagents support histone‑lactylation‑site detection, chromatin‑profiling and mechanistic exploration for microglia‑mediated neuroinflammation experimental workflows.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.

Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.